Six AIS-A quadriplegic volunteers received 10 million AST-OPC1 cells in Asterias Biotherapeutics SCIstar trial. For the five patients who have completed at least 6 months of follow-up all have seen improvements in their motor function, Read more…
Search Results for: 1
Research to reverse spinal cord injury offers renewed hope to 15,000 Australians
Research aiming to reverse the paralyzing effects of spinal cord injuries (SCI) that devastate the lives of so many Australians and their families will soon begin at the University of Technology Sydney (UTS).
Research Roundup December 2015
Four broad areas of research are showing the most promise for spinal cord injury treatments. The frontrunners in each are being tested in people: Pharmacological treatments These include drug therapies which, if administered soon after injury will hopefully reduce the…
Asterias to begin stem cell dose escalation in the Phase 1/2a trial for SCI
The SCiStar Study is a Phase 1/2a clinical trial evaluating the safety and activity of escalating doses of AST-OPC1 cells in newly injured patients with sensory and motor complete cervical spinal cord injury. The three patients in the first cohort…
Implantable tech that restores movement in paralyzed patients available in 2017
Case Western Reserve University’s Institute for Functional Restoration (IFR) and Synapse Biomedical Inc. have entered a partnership to commercialize fully implantable systems that restore muscle function in paralyzed patients. The technology uses electrical stimulation to activate neural pathways and create…
ISSCR 2015: Dr Stephen Huhn presents update on StemCells Inc's progress
1,000 year old remedy kills MRSA superbug
Take cropleek and garlic, of both equal quantities, pound them well together… take wine and bullocks gall, mix with the leek… let it stand nine days in the brass vessel… This ninth-century Anglo-Saxon remedy for eye infections has been found to…
Phase 1/2a stem cell trial for acute spinal cord injury begins
Asterias Biotherapeutics has initiated patient enrolment for its Phase 1/2a clinical trial of AST-OPC1 stem cells for treating newly injured people with complete cervical spinal cord injury. “The Phase 1 study generated a strong package of data regarding the safety of AST-OPC1,” said…
Miami Project Schwann Trial for Chronic SCI Begins Enrollment for 10 people
This new trial will be primarily focused on safety, but in addition it will involve a preliminary evaluation of the efficacy of combining Schwann cells with exercise and rehabilitation. They only have FDA approval to transplant a maximum of 10 people…
Xander cycled 1000Km
and raised $20,000